Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Male Participants Clear all

Conditions: Renal Impairment
Interventions: MK-3402; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Conditions: Healthy, Renal Dysfunction
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Renal Impairment
Interventions: MK-3866; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Chronic Kidney Disease
Interventions: OJR520, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: BMS-986166, Bisacodyl; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Conditions: Healthy
Interventions: LY3214996, [14C]-LY3214996; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatic Impairment, Healthy
Interventions: Palovarotene; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Thrombosis
Interventions: BMS-986177; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hematological Malignancy
Interventions: Nemtabrutinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy Volunteer
Interventions: BIIB800, Actemra; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Renal Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Orlando, Florida • Saint Paul, Minnesota

Conditions: Healthy Participants
Interventions: INCB123667; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure
Interventions: AMG 986; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Cough
Interventions: GSK5464714- Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: Emraclidine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: [14C]-CC-92480; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-DNL343; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Quemliclustat; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: GRT6019; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: tucatinib; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: AG-348, [13C6]AG-348; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

A Study of LY3214996 in Healthy Participants

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348